Corcept Therapeutics Incorporated (CORT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($38.45 Million) by net assets ($647.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Corcept Therapeutics Incorporated - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Corcept Therapeutics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CORT current and long-term liabilities for a breakdown of total debt and financial obligations.
Corcept Therapeutics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inesa Intelligent Tech Inc A
SHG:600602
|
-0.009x |
|
Pan African Resources PLC
JSE:PAN
|
0.064x |
|
Sandstorm Gold Ltd N
TO:SSL
|
0.027x |
|
SEIKO EPSON CORP.ADR 1/2
F:SE7S
|
N/A |
|
Unilever Indonesia Tbk
JK:UNVR
|
0.579x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Organización Soriana S. A. B. de C. V
MX:SORIANAB
|
0.047x |
|
The Marzetti Company
NASDAQ:MZTI
|
0.086x |
Annual Cash Flow Conversion Efficiency for Corcept Therapeutics Incorporated (2003–2025)
The table below shows the annual cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Corcept Therapeutics Incorporated market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $647.80 Million | $142.00 Million | 0.219x | -24.79% |
| 2024-12-31 | $679.59 Million | $198.07 Million | 0.291x | +16.25% |
| 2023-12-31 | $506.70 Million | $127.04 Million | 0.251x | +4.57% |
| 2022-12-31 | $501.84 Million | $120.32 Million | 0.240x | -46.33% |
| 2021-12-31 | $375.81 Million | $167.89 Million | 0.447x | +53.85% |
| 2020-12-31 | $523.34 Million | $151.97 Million | 0.290x | -20.81% |
| 2019-12-31 | $371.18 Million | $136.12 Million | 0.367x | -12.53% |
| 2018-12-31 | $275.88 Million | $115.67 Million | 0.419x | +31.39% |
| 2017-12-31 | $190.97 Million | $60.94 Million | 0.319x | -28.21% |
| 2016-12-31 | $41.38 Million | $18.39 Million | 0.444x | +162.67% |
| 2015-12-31 | $18.50 Million | $3.13 Million | 0.169x | -97.91% |
| 2014-12-31 | $-3.39 Million | $-27.38 Million | 8.080x | +558.26% |
| 2013-12-31 | $21.02 Million | $-37.06 Million | -1.763x | -202.41% |
| 2012-12-31 | $61.78 Million | $-36.02 Million | -0.583x | +25.93% |
| 2011-12-31 | $34.81 Million | $-27.40 Million | -0.787x | +24.96% |
| 2010-12-31 | $21.24 Million | $-22.29 Million | -1.049x | -28.98% |
| 2009-12-31 | $22.09 Million | $-17.97 Million | -0.813x | +25.11% |
| 2008-12-31 | $16.91 Million | $-18.36 Million | -1.086x | -45.95% |
| 2007-12-31 | $14.73 Million | $-10.96 Million | -0.744x | +79.63% |
| 2006-12-31 | $6.36 Million | $-23.24 Million | -3.654x | -463.80% |
| 2005-12-31 | $26.59 Million | $-17.23 Million | -0.648x | -117.07% |
| 2004-12-31 | $45.95 Million | $-13.72 Million | -0.299x | +69.43% |
| 2003-12-31 | $10.24 Million | $-10.00 Million | -0.977x | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more